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Preface to BBA issue devoted to ﬁbrosisInsights emerging from divergent disciplines have generated re-
markable progress in understanding tissue ﬁbrosis. The traditional
view of ﬁbrosis as simply an accumulation of extracellular matrix
molecules has yielded to a more enlightened understanding of the
elements that contribute to this response. The broad collection of
articles by renowned experts in this special issue of BBA encapsulates
this progress and provides a valuable snapshot of the ﬁeld in 2013.
As highly prevalent illnesses such as cardiovascular disease and
cancer have seen steady advances in their treatment, attention has
turned increasingly to those disorders that still lack therapies, yet
exact a substantial health toll worldwide, and few ﬁt this description
better than ﬁbrotic disorders. Estimated to account for up to 45% of all
deaths in the industrialized world [1], chronic scarring of the liver,
lung, kidney, and heart, among others, has no effective treatment,
and there are no FDA- or EMEA-approved anti-ﬁbrotic therapies. Re-
cent review articles have emphasized the clinical opportunities [2,3],
but translational progress will continue to be built upon a foundation
of basic science advances. This issue of BBA is intended to capture
those advances.
The issue is divided into six sections that reﬂect a continuum
beginning with biochemistry and ending with clinical implications:
1) Biochemistry of ﬁbrosis; 2) ECM–cell and cell–cell interactions in
ﬁbrosis; 3) Epithelial injury and EMT in ﬁbrosis; 4) Cellular sources
of ECM in tissue injury; 5) Inﬂammatory and immune interactions
in ﬁbrosis; and 6) Biomarkers and therapeutic strategies in ﬁbrotic
diseases. Importantly, unlike most reviews, the articles cover topics
across a range of tissues as we seek to deﬁne common principles of
tissue ﬁbrosis, since from these principles are likely to emerge broad-
ly effective antiﬁbrotic therapies. On the other hand, there are also
tissue-speciﬁc pathways that might be more attractive therapeutic
targets, since their inhibition is less likely to have a collateral impact
on healthy tissues [4].
As an investigator who has been in ﬁbrosis research for ~30 years, it's
instructive for me to reﬂect upon how far the ﬁeld has come from the
time when most attention was focused on the chemical composition of
scar rather than its cellular origins or the possibility of its regression.
Some controversies remain – for example the role of epithelium as a
source of ECM [5] – while many topics simply didn't exist in the early
1980s, for example autophagy signaling, chemokines, the inﬂammasome,
and ER stress, to name a few. Thus, a collection of articles that captures
these new areas should be of interest to readers who seek to understand
ﬁbrosis from a variety of scientiﬁc perspectives.0925-4439/$ – see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.bbadis.2013.03.003Thanks to the hard work and expertise of the talented authors, I
believe this issue of BBA meaningfully captures the state of the ﬁeld.
I am indebted not only to these valued colleagues, but also to the
staff and editorial leadership of BBA for recognizing the timeliness
of this topic, and for providing the support to make it happen.
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